The use of nanotechnology for medical purposes—nanomedicine—has grown exponentially
over the past few decades. This is exemplified by the US Food and Drug Administration's …

Coronary artery disease (CAD) is one of the most common causes of death worldwide. In the
last decade, significant advancements in CAD treatment have been made. The existing …

Lipid nanoparticles (LNPs) have become the dominant drug delivery technology in industry,
holding the promise to deliver RNA to up or down‐regulate any protein of interest. LNPs …

Preclinical characterization of novel nanotechnology-based formulations is often challenged
by physicochemical characteristics, sterility/sterilization issues, safety and efficacy. Such …

Cardiovascular diseases (CVDs) refer to a collection of conditions characterized by
abnormalities in the cardiovascular system. They are a global problem and one of the …

Tissue plasminogen activator (tPA) is the only FDA approved thrombolytic drug for acute
ischemic stroke but concerns regarding its limitations remain. Here, we developed a new …

Dose control and effectiveness promotion of tissue plasminogen activator (t-PA) for
thrombolysis are vitally important to alleviate serious side effects such as hemorrhage in …

Ischemic stroke is a vascular central nervous system (CNS) disease that leads a disability
and death. Thrombolysis and neuroprotection are the primary treatment strategies of …

Antimicrobial peptides (AMP) are molecules consisting of 12–100 amino acids synthesized
by certain microbes and released extracellularly to inhibit the growth of other microbes …

Cardiovascular disease (CVD) is the leading cause of death worldwide. CVD includes a
group of disorders of the heart and blood vessels such as myocardial infarction, ischemic …